Status: Recruiting
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
The purpose of this study is to assess the PK, tolerability, and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function. The study duration will be up to 40 days, including Screening, Baseline, Study Period, and EOS visit assessments. Rupatadine 10 mg tablet will be administered as single dose.
Participants needed: 48
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Noucor Health S.A.Updated: May 28, 2025Locations: 7
Eligibility criteria
Participant understands the study procedures and agrees to participate in the st... [+31]
Pregnant or lactating women. [+26]